Stephen Graziano，医学博士

临床试验

临床联系

协会/会员

研究抽象

The Cancer and Leukemia Group B (CALGB) is an NCI sponsored national cooperative group whose goal is to conduct clinical trials of new treatments for neoplastic diseases and related science questions. Protocols are developed with intensive peer review and conducted at over 400 hospitals nationwide, 在加拿大, 在欧洲. The SUNY-Health Science Center Network including the Syracuse VA Medical Center is consistently among the top main member institutions in terms of overall accrual of patients to CALGB studies. CALGB进行第一阶段, II, and III multimodality treatment trials, as well as innovative correlative science studies. Current trials test new therapies for cancer of the breast, 肺, 结肠直肠/, 膀胱, 前列腺癌, 淋巴瘤, 和白血病.

Prognostic Factors in Patients with Non-small Cell 肺癌. 与B. Poiesz,. 泰特姆,N. 纽曼和L. Kohman.

Lung cancer is the leading cause of cancer-related mortality in both men and women in the United States. Seventy-five to eighty percent of cases are of non-small cell 肺 cancer (NSCLC) histology (adenocarcinoma, squamous cell and large cell anaplastic carcinoma). The well established negative prognostic factors for patients with NSCLC include higher st年龄, 减肥, poor performance status and the presence of systemic symptoms. 在过去的几年里, our laboratory has investigated the potential prognostic significance of a number of 病理al and biological variables in a large group (n=260) of patients with surgically resected st年龄 I (n=193) and II (n=67) NSCLC. Multivariate analysis of this retrospectively studied group of patients has yielded a small number of independent prognostic factors. The following predicted for overall survival and disease free-survival: N-st年龄, t台, 抗原的, 年龄, 粘蛋白和Ki-67.

We hypothesize that there are important clinical, 病理, and biological factors that predict for patient outcome and that such factors will be clinically useful for identifying patients that could benefit from additional therapy.

选择引用

Mehdi年代.A.塔图姆，A.H.纽曼，n.n.B.甘布尔，G.P. Etzell J.E.韦德尔，n.n.科恩，J.A.Sorscher, S.M.科曼，L.J.格拉齐亚诺，S.L. Prognostic markers in resected st年龄 I and II non-cell 肺 cancer: an analysis of 260 patients with 5 year follow-up. 中华肺癌杂志，1999,1:59-67.

Lilenbaum R.C.赫恩登，J.E.，列表M.A.德什，D.华生，D.M.米勒，A.A.格拉齐亚诺，S.L.佩里，M.C.萨维尔，W.Chahiniam, P.周，J.C.荷兰，J.C.格林，M.R.  Single-年龄nt versus combination chemotherapy in advanced non-small -cell 肺 cancer:  The Cancer and Leukemia Group B (study 9730). 中华临床杂志，2005,23 (3):391 - 396.

格拉齐亚诺,年代.L.赫恩登，II, J.E.索辛斯基，m.s.A.王，X.华生，D.Vokes, E.格林，M.R.  Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive St年龄 Small Cell 肺癌:  Cancer and Leukemia Group B Study 39901.  Journal of Thoracic 肿瘤学, 3:158-162, 2008.